Back to top

Adaptive Biotechnologies (ADPT) Receives a Buy from Piper Sandler

In a report released today, David Westenberg from Piper Sandler reiterated a Buy rating on Adaptive Biotechnologies, with a price target of $27.50....

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Adaptive Biotechnologies Corporation (ADPT)